Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis

Chest

Volumn 137, Issue 1, 2010, Pages 115-121

  Kosoglou, Teddy ^a   Cutler, David L ^c   Staudinger, Heribert ^c   Herron, Jerry M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Research Solutions LLC   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HYDROCORTISONE; MOMETASONE FUROATE; PLACEBO;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT;

EID: 74949113253     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-0235     Document Type: Article

References (16)

1. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. 2007. http://www.nhlbi.nih.gov/guidelines/asthma/ asthupdt.htm. Accessed August 29, 2007.
2. Bernstein DI, Allen DB. Evaluation of tests of hypothalamicpituitary- adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2007; 98 (2): 118-127.
3. Derendorf H, Hochhaus G. What is the best marker for inhaled corticosteroid safety? Allergy Asthma Proc. 2005; 26 (2): 89-93.
4. Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM. Mometasone furoate has minimal effects on the hypothalamicpituitary-adrenal axis when delivered at high doses. Chest. 2000; 118 (6): 1538-1546.
5. Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chloro-fluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest. 2005; 128 (1): 70-77.
6. Bernstein DI, Berkowitz RB, Chervinsky P, et al. Doseranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med. 1999; 93 (9): 603-612.
7. Bousquet J, D'Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J. 2000;16(5):808-816.
8. Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol. 2001; 86 (1): 36-43.
9. Reinberg A, Smolensky MH, D'Alonzo GE, McGovern JP. Chronobiology and asthma. III. Timing corticotherapy to biological rhythms to optimize treatment goals. J Asthma. 1988; 25 (4): 219-248.
10. Asmanex Twisthaler (mometasone furoate inhalation powder). Full Prescribing Information. Kenilworth, NJ: Schering Corporation; 2005.
11. Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med. 2004; 170 (9): 960-966.
12. Casale TB, Nelson HS, Stricker WE, Raff H, Newman KB. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol. 2001;87(5):379-385.
13. Aaronson D, Kaiser H, Dockhorn R, et al. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitaryadrenal axis in asthmatic subjects: a dose-response study. J Allergy Clin Immunol. 1998; 101 (3): 312-319.
14. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353 (5): 487-497.
15. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002; 24 (2): 302-316.
16. Guest JF, Davie AM, Ruiz FJ, Greener MJ. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J. 2005;14(2):88-98.